Skip to main content
Addgene

pLC-HA active Nedd8-P2A-Hygro
(Plasmid #124307)

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 124307 Standard format: Plasmid sent in bacteria as agar stab 1 $85

Backbone

  • Vector backbone
    pLCE
  • Total vector size (bp) 7803
  • Vector type
    Mammalian Expression, Lentiviral
  • Selectable markers
    Hygromycin

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    NEB Stable
  • Copy number
    High Copy

Gene/Insert

  • Gene/Insert name
    Nedd8
  • Species
    H. sapiens (human)
  • Insert Size (bp)
    225
  • Mutation
    Five C-terminal amino acids missing compared to wild-type Nedd8. The cleaved form represents the active form of Nedd8.
  • Entrez Gene
    NEDD8 (a.k.a. NEDD-8)
  • Promoter CMV
  • Tag / Fusion Protein
    • HA (N terminal on insert)

Cloning Information

Resource Information

  • Supplemental Documents
  • A portion of this plasmid was derived from a plasmid made by
    Nedd8 cDNA from Addgene plasmid 18711 was used as a template for PCR amplification and subsequent mutagenesis.

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pLC-HA active Nedd8-P2A-Hygro was a gift from Eva Gottwein (Addgene plasmid # 124307 ; http://n2t.net/addgene:124307 ; RRID:Addgene_124307)
  • For your References section:

    Genome-wide CRISPR screens reveal genetic mediators of cereblon modulator toxicity in primary effusion lymphoma. Patil A, Manzano M, Gottwein E. Blood Adv. 2019 Jul 23;3(14):2105-2117. doi: 10.1182/bloodadvances.2019031732. 10.1182/bloodadvances.2019031732 PubMed 31300418